Vertex Pharmaceuticals Inc. (VRTX)
  • Россия
  • Украина

Vertex Pharmaceuticals Inc. (VRTX)

Contact Details

50 Northern Ave, Boston, Massachusetts, USA 02210-1862
(617) 341-6100
50 Northern Ave, Boston, Massachusetts, USA 02210-1862

General Information

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Contact Information

Phone(617) 341-6100
Customer Service Phone(800) 947-5227
Fax(617) 444-6773
Website 1
Thomson Reuters PermID4295908317


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO, Chairman of the Board and President$36,635,4682014179.1%
CFO and Executive VP$15,303,8632014265.7%
Executive VP and Chief Medical Officer$13,796,0922014
Former Executive VP and Former Other Executive Officer$9,907,1332014118.2%
Executive VP and Other Executive Officer$15,197,6132014215.4%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsOctober 09, 2012$0
Department of Veterans AffairsDrugs and BiologicalsMay 25, 2011$0

Corporate Data


  • Pharmaceutical Preparation Manufacturing
  • Research and Development in Biotechnology

SIC Industries

  • Pharmaceutical Preparations
  • Biotechnical Research, Commercial

Company Size

Sales Volume$1.03 billion


Ticker SymbolVRTX
ExchangeNASDAQ Global Select Market
Federal Awards
  • Receives Contracts
  • Receives Contracts and Grants
  • Receives Grants
State of IncorporationMassachusetts
Year Founded1989


Previous Close85.25
Bid84.44 x 300
Ask84.47 x 27,500
Day`s Range84.06 - 86.79
52-Week Range78.4 - 141.48
Average Volume (1M)2,174,672
Forward P/E61.78x
Market Cap.$21,004.9 Million
Last Dividend Amount0
1y Target Price Est.141.54


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue417,935309,816166,076138,509
Cost of Revenue63,38531,96016,86012,307
Gross Profit354,550277,856149,216126,202
Research Development310,181246,284223,858215,599
Selling General and Administrative96,54999,77294,39485,860
Depreciation and Amortization----
Other Operating Expenses1,524.11,8262,128(3,272)
Total Operating Expenses471,639.1379,842337,240310,494
Other Income/Expenses Net(0.1)---
Earnings Before Interest and Taxes(53,704.1)(70,026)(171,164)(171,985)
Interest Expense20,65421,13421,11121,307
Income Before Tax(76,048)(92,486)(190,861)(198,405)
Income Tax Expense(1,379)1,33030,131299
Minority Interest----
Net Income from Continuing Ops(74,669)(93,816)(220,992)(198,704)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items937.9(1,333)32,14498
Net Income(73,731.1)(95,149)(188,848)(198,606)
Preferred Stock and Other Adjustments(0.1)---
Net Income Applicable to Common Shares(73,731)(95,149)(188,848)(198,606)